Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

INTRODUCTION: Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended interval dosing (EID) of natalizumab to reduce PML risk, desp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelle, Juliette, Briant, Anais R., Branger, Pierre, Derache, Nathalie, Arnaud, Charlotte, Lebrun-Frenay, Christine, Cohen, Mikael, Mondot, Lydiane, De Seze, Jerome, Bigaut, Kevin, Collongues, Nicolas, Kremer, Laurent, Ricard, Damien, Bompaire, Flavie, Ohlmann, Charlotte, Sallansonnet-Froment, Magali, Ciron, Jonathan, Biotti, Damien, Pignolet, Beatrice, Parienti, Jean-Jacques, Defer, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043118/
https://www.ncbi.nlm.nih.gov/pubmed/36763307
http://dx.doi.org/10.1007/s40120-023-00440-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043118/
https://www.ncbi.nlm.nih.gov/pubmed/36763307
http://dx.doi.org/10.1007/s40120-023-00440-5

Ejemplares similares